In the first group, we injected HT1080 tumor cells alone subcutaneously into the flank; in the second group, tumor cells and RevCAR T-cells; and in the third group, tumor cells, RevCAR T-cells and PD-L1 RevTM. This evidence concerns the gene CD274 and neoplasm.